{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T16:42:32Z","timestamp":1786207352540,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant therapy (NAT) is increasingly used for resectable and borderline-resectable pancreatic ductal adenocarcinoma (PDAC), yet interpretation of treatment response remains challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A single-center retrospective review was conducted of patients with resectable or borderline-resectable PDAC treated with multiagent NAT between 2008 and 2024. Radiographic response was assessed using RECIST 1.1\u00a0criteria, biochemical response by serum CA 19-9 reduction, and histopathologic response by College of American Pathologists (CAP) score. Primary and secondary outcomes were overall survival (OS) and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 166 patients, 148 (89%) completed NAT and 121 (73%) underwent resection. After NAT, radiographic response was uncommon: 27% had tumor regression, 66% stable disease, and 7% progressive disease. By contrast, 83% achieved \u2265\u200945% CA 19-9 reduction after NAT, and 74% demonstrated histopathologic response after resection, including 8% complete pathologic response. Among resected patients with radiographically stable\/progressive disease, 88% had biochemical response and 68% at least partial histopathologic response. Neither radiographic nor biochemical response were significantly associated with improved PFS or OS. Histopathologic response (CAP 0\u20132) was associated with improved PFS\/OS on univariable analysis as well as improved PFS on multivariable analysis [adjusted hazard ratio (aHR) 0.57, 95% confidence interval (CI) 0.34\u20130.96;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034]. Isolated unresectable local progression during NAT was rare (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While imaging response and downstaging can occur with NAT, histopathologic response is more predictive of long-term survival and often occurs despite stable or progressive disease on imaging. Isolated unresectable local progression after NAT is rare, though broader treatment-related attrition remains a consideration in neoadjuvant sequencing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19990-7","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:10:22Z","timestamp":1781867422000},"page":"8448-8458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1245","volume":"33","author":[{"given":"Paul H.","family":"McClelland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan A.","family":"Satyadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosetta","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shesh","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davendra","family":"Sohal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olugbenga","family":"Olowokure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Kharofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory C.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"19990_CR1","unstructured":"National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html"},{"issue":"5","key":"19990_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2217\/fon.15.335","volume":"12","author":"S Russo","year":"2016","unstructured":"Russo S, Ammori J, Eads J, Dorth J. The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncol. 2016;12(5):669\u201385. https:\/\/doi.org\/10.2217\/fon.15.335.","journal-title":"Future Oncol."},{"issue":"6","key":"19990_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","volume":"15","author":"JP Neoptolemos","year":"2018","unstructured":"Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333\u201348. https:\/\/doi.org\/10.1038\/s41575-018-0005-x.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"8","key":"19990_CR4","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca Di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186(8):1729\u201354. https:\/\/doi.org\/10.1016\/j.cell.2023.02.014.","journal-title":"Cell."},{"issue":"9","key":"19990_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851. https:\/\/doi.org\/10.1001\/jama.2021.13027.","journal-title":"JAMA."},{"issue":"5","key":"19990_CR6","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267(5):936\u201345. https:\/\/doi.org\/10.1097\/SLA.0000000000002234.","journal-title":"Ann Surg."},{"issue":"5","key":"19990_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","volume":"20","author":"C Springfeld","year":"2023","unstructured":"Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20(5):318\u201337. https:\/\/doi.org\/10.1038\/s41571-023-00746-1.","journal-title":"Nat Rev Clin Oncol."},{"issue":"7","key":"19990_CR8","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","volume":"4","author":"JE Murphy","year":"2018","unstructured":"Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 Clinical Trial. JAMA Oncol. 2018;4(7):963. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0329.","journal-title":"JAMA Oncol."},{"issue":"8","key":"19990_CR9","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jnci\/djz073","volume":"111","author":"QP Janssen","year":"2019","unstructured":"Janssen QP, Buettner S, Suker M, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111(8):782\u201394. https:\/\/doi.org\/10.1093\/jnci\/djz073.","journal-title":"J Natl Cancer Inst."},{"issue":"18","key":"19990_CR10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med."},{"key":"19990_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","volume":"160","author":"JL Van Dam","year":"2022","unstructured":"Van Dam JL, Janssen QP, Besselink MG, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. Eur J Cancer. 2022;160:140\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2021.10.023.","journal-title":"Eur J Cancer."},{"issue":"1","key":"19990_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11605-013-2412-1","volume":"18","author":"CWD Tzeng","year":"2014","unstructured":"Tzeng CWD, Cao HST, Lee JE, et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014;18(1):16\u201325. https:\/\/doi.org\/10.1007\/s11605-013-2412-1.","journal-title":"J Gastrointest Surg."},{"issue":"3","key":"19990_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jso.24316","volume":"114","author":"EA Asare","year":"2016","unstructured":"Asare EA, Evans DB, Erickson BA, Aburajab M, Tolat P, Tsai S. Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. J Surg Oncol. 2016;114(3):291\u20135. https:\/\/doi.org\/10.1002\/jso.24316.","journal-title":"J Surg Oncol."},{"issue":"2","key":"19990_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00261-017-1434-7","volume":"43","author":"V Baliyan","year":"2018","unstructured":"Baliyan V, Kordbacheh H, Parakh A, Kambadakone A. Response assessment in pancreatic ductal adenocarcinoma: role of imaging. Abdom Radiol. 2018;43(2):435\u201344. https:\/\/doi.org\/10.1007\/s00261-017-1434-7.","journal-title":"Abdom Radiol."},{"issue":"23","key":"19990_CR15","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1002\/cncr.27636","volume":"118","author":"MHG Katz","year":"2012","unstructured":"Katz MHG, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749\u201356. https:\/\/doi.org\/10.1002\/cncr.27636.","journal-title":"Cancer."},{"issue":"5","key":"19990_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.amjsurg.2012.07.007","volume":"204","author":"JL Welsh","year":"2012","unstructured":"Welsh JL, Bodeker K, Fallon E, Bhatia SK, Buatti JM, Cullen JJ. Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma. Am J Surg. 2012;204(5):580\u20135. https:\/\/doi.org\/10.1016\/j.amjsurg.2012.07.007.","journal-title":"Am J Surg."},{"issue":"2","key":"19990_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188409","volume":"1875","author":"G Luo","year":"2021","unstructured":"Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer: biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188409. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188409.","journal-title":"Biochim Biophys Acta Rev Cancer."},{"issue":"7","key":"19990_CR18","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdr561","volume":"23","author":"JL Humphris","year":"2012","unstructured":"Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serum CA19-9 in pancreatic cancer. Ann Oncol. 2012;23(7):1713\u201322. https:\/\/doi.org\/10.1093\/annonc\/mdr561.","journal-title":"Ann Oncol."},{"issue":"6","key":"19990_CR19","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1245\/s10434-019-08156-3","volume":"27","author":"AI Al Abbas","year":"2020","unstructured":"Al Abbas AI, Zenati M, Reiser CJ, et al. Serum CA19-9 response to neoadjuvant therapy predicts tumor size reduction and survival in pancreatic adenocarcinoma. Ann Surg Oncol. 2020;27(6):2007\u201314. https:\/\/doi.org\/10.1245\/s10434-019-08156-3.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"19990_CR20","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1245\/s10434-014-3842-z","volume":"21","author":"BA Boone","year":"2014","unstructured":"Boone BA, Steve J, Zenati MS, et al. Serum CA 19\u20139 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014;21(13):4351\u20138. https:\/\/doi.org\/10.1245\/s10434-014-3842-z.","journal-title":"Ann Surg Oncol."},{"key":"19990_CR21","doi-asserted-by":"publisher","first-page":"153303382110430","DOI":"10.1177\/15330338211043030","volume":"20","author":"YM Kang","year":"2021","unstructured":"Kang YM, Wang H, Li R, Pan G. Prognostic role of carbohydrate antigen 19 to 9 in predicting survival of patients with pancreatic cancer: a meta-analysis. Technol Cancer Res Treat. 2021;20:15330338211043030. https:\/\/doi.org\/10.1177\/15330338211043030.","journal-title":"Technol Cancer Res Treat."},{"issue":"1","key":"19990_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/bjs\/znac350","volume":"110","author":"BV Janssen","year":"2022","unstructured":"Janssen BV, van Roessel S, van Dieren S, et al. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Br J Surg. 2022;110(1):67\u201375. https:\/\/doi.org\/10.1093\/bjs\/znac350.","journal-title":"Br J Surg."},{"issue":"1","key":"19990_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5858\/arpa.2011-0144-RA","volume":"136","author":"DJ Hartman","year":"2012","unstructured":"Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. 2012;136(1):100\u20139. https:\/\/doi.org\/10.5858\/arpa.2011-0144-RA.","journal-title":"Arch Pathol Lab Med."},{"issue":"1","key":"19990_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41379-020-00683-9","volume":"34","author":"BV Janssen","year":"2021","unstructured":"Janssen BV, Tutucu F, Van Roessel S, et al. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Modern Pathol. 2021;34(1):4\u201312. https:\/\/doi.org\/10.1038\/s41379-020-00683-9.","journal-title":"Modern Pathol."},{"issue":"3","key":"19990_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/SLA.0000000000004155","volume":"272","author":"SA Ahmad","year":"2020","unstructured":"Ahmad SA, Duong M, Sohal DPS, et al. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine\/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. Ann Surg. 2020;272(3):481\u20136. https:\/\/doi.org\/10.1097\/SLA.0000000000004155.","journal-title":"Ann Surg."},{"issue":"4","key":"19990_CR26","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/jso.24538","volume":"115","author":"BT Xia","year":"2017","unstructured":"Xia BT, Fu B, Wang J, et al. Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? J Surg Oncol. 2017;115(4):376\u201383. https:\/\/doi.org\/10.1002\/jso.24538.","journal-title":"J Surg Oncol."},{"issue":"12","key":"19990_CR27","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.diii.2016.07.011","volume":"97","author":"C Cassinotto","year":"2016","unstructured":"Cassinotto C, Sa-Cunha A, Trillaud H. Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. Diagn Interv Imaging. 2016;97(12):1225\u201332. https:\/\/doi.org\/10.1016\/j.diii.2016.07.011.","journal-title":"Diagn Interv Imaging."},{"issue":"4","key":"19990_CR28","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1245\/s10434-008-0295-2","volume":"16","author":"MHG Katz","year":"2009","unstructured":"Katz MHG, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(4):836\u201347. https:\/\/doi.org\/10.1245\/s10434-008-0295-2.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"19990_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/SLA.0000000000002600","volume":"269","author":"T Michelakos","year":"2019","unstructured":"Michelakos T, Pergolini I, Castillo CFD, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2019;269(4):733\u201340. https:\/\/doi.org\/10.1097\/SLA.0000000000002600.","journal-title":"Ann Surg."},{"issue":"7","key":"19990_CR30","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1245\/s10434-010-0943-1","volume":"17","author":"MHG Katz","year":"2010","unstructured":"Katz MHG, Varadhachary GR, Fleming JB, et al. Serum CA 19\u20139 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17(7):1794\u2013801. https:\/\/doi.org\/10.1245\/s10434-010-0943-1.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"19990_CR31","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.hpb.2020.01.013","volume":"22","author":"JM Cloyd","year":"2020","unstructured":"Cloyd JM, Ejaz A, Shen C, et al. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. HPB (Oxford). 2020;22(11):1569\u201376. https:\/\/doi.org\/10.1016\/j.hpb.2020.01.013.","journal-title":"HPB (Oxford)."},{"issue":"8","key":"19990_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.1137","volume":"151","author":"MHG Katz","year":"2016","unstructured":"Katz MHG, Shi Q, Ahmad SA, et al. Preoperative Modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016;151(8):e161137. https:\/\/doi.org\/10.1001\/jamasurg.2016.1137.","journal-title":"JAMA Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19990-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19990-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19990-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:48:41Z","timestamp":1786204121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19990-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["19990"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19990-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}